Milestones in camptothecin research

被引:30
作者
Lerchen, HG [1 ]
机构
[1] Bayer AG, BHC PHREU, D-51368 Leverkusen, Germany
关键词
D O I
10.1358/dof.2002.027.09.694498
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The discovery of the natural product camptothecin in the early 1960s provided the lead structure for a novel, highly promising class of antitumor agents. Significant progress involving the understanding of the mechanism of action, the drug metabolism, chemistry driven analoging programs and clinical research for dose and schedule optimization led to major breakthroughs in the field. Today, with two successful compounds in clinical practice (irinotecen and topotecan) and more than 10 clinical development programs, the campothecins have reached a very high clinical relevance.
引用
收藏
页码:869 / 878
页数:10
相关论文
共 82 条
[21]  
GOTTLIEB JA, 1970, CANCER CHEMOTH REP 1, V54, P461
[22]   Drug delivery systems .2. Camptothecin 20-O-poly(ethylene glycol)ester transport forms [J].
Greenwald, RB ;
Pendri, A ;
Conover, C ;
Gilbert, C ;
Yang, R ;
Xia, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (10) :1938-1940
[23]   Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity [J].
Greenwald, RB ;
Pendri, A ;
Conover, CD ;
Lee, C ;
Choe, YH ;
Gilbert, C ;
Martinez, A ;
Xia, J ;
Wu, DC ;
Hsue, M .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (05) :551-562
[24]   Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate [J].
Harada, M ;
Sakakibara, H ;
Yano, T ;
Suzuki, T ;
Okuno, S .
JOURNAL OF CONTROLLED RELEASE, 2000, 69 (03) :399-412
[25]   MODIFICATION OF THE HYDROXY LACTONE RING OF CAMPTOTHECIN - INHIBITION OF MAMMALIAN TOPOISOMERASE-I AND BIOLOGICAL-ACTIVITY [J].
HERTZBERG, RP ;
CARANFA, MJ ;
HOLDEN, KG ;
JAKAS, DR ;
GALLAGHER, G ;
MATTERN, MR ;
MONG, SM ;
BARTUS, JO ;
JOHNSON, RK ;
KINGSBURY, WD .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (03) :715-720
[26]   Schedule-dependent efficacy of camptothecins in models of human cancer [J].
Houghton, PJ ;
Stewart, CF ;
Zamboni, WC ;
Thompson, J ;
Luo, XLL ;
Danks, MK ;
Houghton, JA .
CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT, 1996, 803 :188-201
[27]  
HSIANG YH, 1985, J BIOL CHEM, V260, P4873
[28]  
HSIANG YH, 1989, CANCER RES, V49, P4385
[29]   Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J].
Huinink, WTB ;
Gore, M ;
Carmichael, J ;
Gordon, A ;
Malfetano, J ;
Hudson, I ;
Broom, C ;
Scarabelli, C ;
Davidson, N ;
Spanczynski, M ;
Bolis, G ;
Malmstrom, H ;
Coleman, R ;
Fields, SC ;
Heron, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2183-2193
[30]  
Humerickhouse R, 2000, CANCER RES, V60, P1189